RCT Spells Requirement For Lipidryl, Shrinking Beauty Weight Loss Claims
This article was originally published in The Tan Sheet
Executive Summary
Although FTC orders for RCTs to substantiate claims are criticized by some industry stakeholders, the agency routinely includes the burden of clinical trials in settlements with firms found to conduct false and misleading advertising for consumer health products, particularly in the weight loss area.
You may also be interested in...
Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads
An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.
In Brief
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: